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Abstract A recombinant non-glycosylated and acidic form of
avidin was designed and expressed in soluble form in baculovirus-
infected insect cells. The mutations were based on the same
principles that guided the design of the chemically and
enzymatically modified avidin derivative, known as NeutraLite
Avidin. In this novel recombinant avidin derivative, five out of the
eight arginine residues were replaced with neutral amino acids,
and two of the lysine residues were replaced by glutamic acid. In
addition, the carbohydrate-bearing asparagine-17 residue was
altered to an isoleucine, according to the known sequences of
avidin-related genes. The resultant mutant protein, termed
recombinant NeutraLite Avidin, exhibited superior properties
compared to those of avidin, streptavidin and the conventional
NeutraLite Avidin, prepared by chemo-enzymatic means. In this
context, the recombinant mutant is a single molecular species,
which possesses strong biotin-binding characteristics. Due to its
acidic pI, it is relatively free from non-specific binding to DNA
and cells. The recombinant NeutraLite Avidin retains seven
lysines per subunit, which are available for further conjugation
and derivatization.
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1. Introduction
Avidin is a tetrameric glycoprotein isolated from chicken
egg white. The ability of avidin to bind biotin with exception-
ally high a⁄nity (KdV10315M) [1] has been the basis for its
exploitation as a molecular tool in biotechnological, diagnos-
tic and therapeutic applications, collectively known as avidin-
biotin technology [2^4]. The avidin tetramer consists of four
identical subunits, all bearing 128 amino acids and possessing
one biotin-binding site [5]. The protein is basically charged
(pIV10.5), and each of its monomers possesses eight arginine
and nine lysine residues [5]. The polypeptide chain of avidin
also contains a glycosylation site at residue Asn-17. The car-
bohydrate moiety accounts for about 10% of the molecular
mass of avidin and exhibits extensive glycan microheterogene-
ity [6].
Despite the utility of chicken avidin in the many applica-
tions of avidin-biotin technology, there are some drawbacks
associated with its use. Its high pI and the presence of carbo-
hydrate can cause non-speci¢c binding to extraneous material
in certain applications, and these properties, therefore, hinder
its use. Due to these di⁄culties, streptavidin, a non-glycosy-
lated and neutrally charged bacterial counterpart of avidin [7],
has virtually replaced avidin in these applications, even
though avidin contains more lysine residues for potential at-
tachment of probes, is more hydrophilic, and is considerably
more abundant and cheaper than streptavidin.
In our attempts to improve the physicochemical properties
of chicken avidin, we have shown earlier, that the oligosac-
charide moiety can be removed enzymatically [8^10]. The re-
sultant deglycosylated product can recognize biotin with high
a⁄nity constant, similar to that of the native glycoprotein. On
the basis of the latter ¢nding, the non-glycosylated and neu-
tral avidin derivative, called NeutraLite Avidin (Belovo
Chemicals, Bastogne, Belgium) or NeutrAvidin (Pierce, Rock-
ford, IL, USA) was developed.
Using protein engineering techniques, we further demon-
strated in a recent study [11] that the high pI of avidin can
be reduced down to 4.7 by replacing arginines and lysines with
neutral or acidic amino acids. The resultant mutant retained
most of its lysine residues intact and available for further
derivatization with, or attachment to, desired probes. More-
over, the biotin-binding capacity and stability of the avidin
tetramer were maintained.
In the present work, we ¢rst modi¢ed by genetic means the
glycosylation site of avidin, in order to produce an avidin
mutant without the oligosaccharide moiety. It was especially
of interest to determine whether removal of the sugar moiety
by protein engineering would a¡ect the biotin-binding ca-
pacity or the stability properties of the non-glycosylated avi-
din mutant. Secondly, we wanted to combine this sugarless
mutant with the previously published charge mutant, Avm-
pI4.7 [11], to further improve the non-speci¢c binding charac-
teristics of avidin. The ensuing mutant avidins, expressed in
baculovirus-infected insect cells, displayed biotin-binding ac-
tivity comparable with that of the wild-type avidin. Moreover,
the combined mutant, ngAvm-pI4.7, showed clearly reduced
non-speci¢c binding to DNA and di¡erent cells, and therefore
this mutant form of chicken avidin is particularly appropriate
for general application in avidin-biotin technology.
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2. Materials and methods
2.1. Site-directed mutagenesis and preparation of avidin mutants
Mutagenesis of avidin cDNA [12] was accomplished by the PCR-
based megaprimer method using Pfu DNA polymerase (Stratagene,
La Jolla, CA, USA) as described earlier [11]. Infection of Sf 9 insect
cells and puri¢cation of avidin mutants by a⁄nity chromatography on
2-iminobiotin-agarose were also reported earlier [11,13].
2.2. Protein analyses
Several of the comparative assays of avidin and mutants used in
this work have been described in earlier publications. The quaternary
status of avidin was analyzed by FPLC on a recently calibrated Super-
ose 12 column (Pharmacia) using an LKB HPLC system [14]. A
sample (40 Wg in 100 Wl of phosphate bu¡er with 0.65 M NaCl, pH
7.2) was applied, and chromatography was carried out at a £ow rate
of 0.5 ml/min, using the same ionic strength in the equilibration and
running bu¡ers. Binding kinetics were measured in a 2-iminobiotin
cuvette, using optical biosensor technology (IASys Manual+, A⁄nity
Sensors, Cambridge, UK) [11]. The thermal stability characteristics of
the avidin mutants were assessed electrophoretically as described pre-
viously [15]. Protease sensitivity was determined according to Laitinen
et al. [14]. Electrophoretic analysis was carried out using 15% (w/v)
SDS^PAGE in a discontinuous bu¡er system [15,16].
2.3. Non-speci¢c binding assay
Non-speci¢c binding of avidin and mutants was examined by slot-
blot assay using a Bio-dot0 SF micro¢ltration apparatus (Bio-Rad
Laboratories, Hercules, CA, USA). Successive dilutions of salmon-
sperm DNA (10, 3, 1 and 0.3 Wg in 50 Wl of 2USSC solution) were
¢xed to the slots according to the manufacturer’s instructions. The
dried strips were quenched using 5UDenhart’s solution. The desired
avidin or mutant sample (25 Wg in 1 ml of 5UDenhart’s solution per
5 cm2 nitrocellulose strip) was then added and incubated at room
temperature for 90 min. The strips were then washed with PBS/
0.05% Tween 20 solution, quenched with 0.5% BSA, and stained
immunochemically as described earlier [13].
The test for non-speci¢c binding to di¡erent cells was performed as
follows. The cells chosen for this work were human platelets and
lymphocytes, mouse hepatocytes, and Escherichia coli strain HB101,
grown to the early logarithmic phase. Cell samples (V2.5 Wg protein)
were introduced into the slots. The cell suspension was allowed to dry
by applying gentle vacuum, thus ¢xing the cells to the nitrocellulose
membranes. The slot blots were quenched using 0.5% BSA, challenged
by the desired avidin sample (2.5 Wg in 50 Wl PBS per slot). In both
previous steps, the solutions were allowed to interact for 30 min prior
to their evacuation. In between all steps, the blots were washed ex-
tensively using PBS/0.05% Tween 20 solution. The nitrocellulose
membrane was removed from the apparatus, quenched again, and
the bound avidin or derivative was detected immunochemically [13].
3. Results
3.1. Design of avidin mutants
We have recently reported the construction of fully func-
tional avidin mutants, which exhibit pI values ranging from
9.4 down to 4.7 [11]. The mutations were devised by rational
design, using sequence comparisons of streptavidin [17], the
recently cloned avidin-related (avr) genes [18,19] and observa-
tions of the crystallographic structure of avidin [20^22]. By
using the same general concept, we have now modi¢ed the
glycosylation site of the avidin polypeptide chain, in order
to produce a recombinant non-glycosylated avidin (ngAvm).
This was accomplished by site-directed mutagenesis of Asn-17
to Ile. Isoleucine was chosen rather than alanine, because all
avr proteins have Ile at this position (Fig. 1) and they all bind
biotin strongly (K.J. Airenne, unpublished results). To further
modify the properties of avidin we also combined the sugar-
less mutant ngAvm with the previously published charge mu-
tant Avm-pI4.7 [11]. Of the six di¡erent reduced charge mu-
tants reported in that study, Avm-pI4.7 was selected, since it
displayed very tight biotin binding properties and was shown
to be very stable. A list of the mutants used in this study is
given in Table 1.
3.2. Production and puri¢cation of mutant avidins
Our previous results have shown that both avidin [13] and
avidin mutants [11,14] can be e⁄ciently produced in Sf9 insect
cells, using a baculovirus expression system. Indeed, the ex-
pression of non-glycosylated avidin, ngAvm, was comparable
to that of the wild-type avidin, although its secretion into the
culture medium was clearly diminished (data not shown). The
same phenomenon was also observed with the acidic, non-
glycosylated derivative, ngAvm-pI4.7. A⁄nity chromatogra-
phy on 2-iminobiotin agarose was used to purify the mutant
avidins in one step to 95% homogeneity, as judged from SDS^
PAGE. In the production of these proteins, a biotin-free cul-
ture medium was used, since the presence of biotin in the
medium hinders subsequent a⁄nity puri¢cation by blocking
the binding sites of avidin and its mutants. The ¢nal yields of
the mutant avidins were between 7 and 9 mg per liter culture.
3.3. Protein chemical analysis
As previously reported [15], at low temperatures wild-type
avidin formed aggregates and failed to penetrate the separat-
ing gel in SDS^PAGE analysis (Fig. 2). This aggregation is
presumably caused by the interaction of the negatively
charged detergent with the positively charged tetrameric pro-
Fig. 1. Sequence alignment of the oligosaccharide-linkage site of na-
tive avidin and avidin-related proteins. The oligosaccharide linkage
site of the native chicken avidin sequence is shaded and positioned
in the middle of the second L-strand (indicated by the arrow).
Note: all of the avr’s bear an isoleucine at position 17, instead of
the asparagine residue of the native avidin.
Table 1
Mutant avidins used in this study
Mutant Description Mutations
Avm-pI4.7 Recombinant acidic mutant of chicken avidin, having seven mutated residues
(basic-to-neutral or basic-to-acidic) and exhibiting a pI of 4.7 [11].
R2A, K3E, K9E, R26N,
R59A, R122A, R124A
ngAvm Non-glycosylated mutant of avidin, carrying an asparagine-to-isoleucine mutation
at residue 17.
N17I
ngAvm-pI4.7 A combined acidic, non-glycosylated mutant, containing all of the mutated residues
carried by the above two mutants.
N17I, R2A, K3E, K9E, R26N,
R59A, R122A, R124A
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tein. At higher temperatures, the aggregates dissociate, and
the protein penetrates the gel as a monomer. The same phe-
nomenon was observed with ngAvm, but, interestingly, under
similar non-denaturing conditions, both acidic mutants (Avm-
pI4.7 and ngAvm-pI4.7) migrated in the separating gel in a
manner consistent with that of the tetramer.
The quaternary status of the ngAvm, Avm-pI4.7 and
ngAvm-pI4.7, in the presence and in the absence of biotin,
was examined by FPLC on a Superose 12 column (data not
shown). Comparison of the elution pro¢les with molecular
mass standards showed that they behaved similar to wild-
type avidin forming stable tetramers.
3.4. Biotin-binding activity
We have previously reported that the biotin-binding activity
of Avm-pI4.7 was similar to that of the wild-type avidin [11].
It was also clear from the puri¢cation results, that ngAvm and
ngAvm-pI4.7 both bound strongly to 2-iminobiotin, since
they were e⁄ciently a⁄nity puri¢ed using this biotin deriva-
tive as a capturing ligand. An optical biosensor (IASyS Man-
ual+) was used to further analyze the biotin-binding activities
of ngAvm and ngAvm-pI4.7. However, the binding of these
proteins to immobilized biotin was so strong that practically
no dissociation was observed (data not shown). This already
indicated that ngAvm and ngAvm-pI4.7 displayed very high
a⁄nity for biotin. In order to obtain more precise data on
possible di¡erences in binding a⁄nities, 2-iminobiotin was
used as a ligand instead of biotin. 2-Iminobiotin is a biotin
analog, which binds avidin reversibly in a pH-dependent man-
ner under relatively mild conditions [23]. The analysis of the
binding curves of ngAvm, Avm-pI4.7 and ngAvm-pI4.7
showed that these mutations had only a nominal a¡ect on
the kinetic parameters of binding to 2-iminobiotin when com-
pared to wild-type avidin (Table 2). The calculated kon and
koff values (and, consequently, the KD values as well) for these
three mutants were found to be similar to those of wild-type
avidin, suggesting that their biotin-binding activity was rela-
tively una¡ected by the changes in the amino acid sequence.
3.5. Stability of avidin mutants
The thermal stability of ngAvm and ngAvm-pI4.7 was com-
pared with that of the wild-type avidin by SDS^PAGE assay
[15]. For this purpose the proteins were diluted in SDS-con-
taining bu¡er and incubated at temperatures between 25‡C
and 100‡C in the absence and presence of biotin, and the
dissociation of the tetrameric to the monomeric form was
observed. The ratio of tetramer to monomer was quanti¢ed
by analyzing the densitometry tracings of the individual lanes
and by plotting these values as a function of temperature (Fig.
3). In the absence of biotin, the tetramer-to-monomer transi-
tion of wild-type avidin occurred over a temperature range
between 50‡C and 70‡C. On the other hand, the binding of
biotin further stabilized the native protein so that tempera-
tures near 100‡C were required for dissociation to begin. The
thermal stability properties of ngAvm were fully comparable
with that of the wild-type avidin both with and without bio-
tin. As previously reported [11], the Avm-pI4.7 also displayed
very similar thermal stability characteristics when compared
to that of the wild-type avidin. The ngAvm-pI4.7 was also
found to be a very stable protein, although it exhibited
slightly diminished thermostability both in the presence and
in the absence of biotin.
To further investigate the stability of the avidin mutants, we
tested their sensitivity to proteolysis by using a proteinase K
Fig. 2. SDS^PAGE of native and mutated avidins. Samples (1 mg/
ml) of the native protein (Avidin), the N17I-mutated (non-glycosy-
lated) derivative (ngAvm), the pI 4.7 mutant (Avm-pI4.7) and the
combined non-glycosylated, pI 4.7 mutant (ngAvm-pI4.7) were di-
luted in SDS-containing sample bu¡er and subjected to non-dena-
turing (25‡C) and denaturing (100‡C) conditions prior to electropho-
resis. Note, the native avidin and non-glycosylated mutant (i.e. the
basically charged proteins) fail to penetrate the gel under non-dena-
turing conditions, whereas the acidic mutants migrate according to
their expected molecular weight values.
Fig. 3. Temperature-dependent dissociation of native and mutated
avidins and their complexes with biotin. Samples of biotin-free and
biotin-saturated avidin or avidin mutant were combined with sample
bu¡er, incubated for 20 min at the designated temperatures, and
subjected to SDS^PAGE in 15% separating gels. Densitometry trac-
ings from each of the Coomassie-stained gels were graphed as a
function of temperature.
Table 2
Kinetic parameters for binding of avidin and di¡erent mutants to 2-
iminobiotin at pH 9.5
Protein kon (M31 s31) koff (s31) KD (M)
Avidin 1.6U104 3.1U1034 2.0U1038
Avm-pI4.7 1.6U104 2.0U1034 1.3U1038
ngAvm 1.9U104 6.6U1034 3.5U1038
ngAvm-pI4.7 3.3U104 7.1U1034 2.2U1038
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assay system. It has been previously reported [24] that apo-
avidin is susceptible to slow limited proteolysis by proteinase
K, whereas holoavidin is stable even in the presence of high
amounts of the enzyme. Avidin and its mutants were thus
incubated with proteinase K at 37‡C, and samples were taken
at predetermined time intervals. The samples were then sub-
jected to SDS^PAGE, and the amount of intact protein in
each lane was determined by densitometry and compared to
that of an untreated control sample. The results were graphed
as stability to protease treatment vs. time of the reaction (Fig.
4). As expected, without biotin the wild-type avidin was sus-
ceptible to slow proteolysis, but in the presence of biotin the
native glycoprotein was stable. Likewise, the glycosylated mu-
tant (Avm-pI4.7) displayed very similar behavior to wild-type
avidin. In contrast, both non-glycosylated proteins (ngAvm
and ngAvm-pI4.7) were clearly less stable in the absence of
biotin. The binding of biotin, however, stabilized these pro-
teins and rendered them resistant to proteinase K.
3.6. Non-speci¢c binding characteristics of avidin mutants
For the present study, a slot-blot assay was developed to
investigate the non-speci¢c binding characteristics of avidin
and its mutants to DNA and to various representative cell
types (Fig. 5). Wild-type avidin bound strongly to DNA as
expected. Most of this binding seemed to be charge-related,
since there was a clear correlation between lowering the iso-
electric point and reduced binding to DNA. Reducing the
positive charge of avidin also drastically lowered the binding
to all four di¡erent cell types used in this study, although
Avm-pI4.7 still exhibited low levels of non-speci¢c binding
to certain cell types (i.e. hepatocytes and lymphocytes). As
expected, ngAvm also bound strongly to DNA and to the
di¡erent cell types. Interestingly, the removal of sugar from
Avm-pI4.7 (i.e. ngAvm-pI4.7) further decreased its binding to
di¡erent cells, such that no binding could be detected, as was
the case with streptavidin.
4. Discussion
Over the past two decades, the avidin-biotin system has
been developed for general applications in the life sciences
[2^4]. The technology has also been used recently in targeted
drug imaging and as an agent for delivery systems in medicine
[25^28]. However, the presence of sugar and the positive
charge of avidin can be a hindrance to its use in these appli-
cations, due to non-speci¢c binding to extraneous material.
In attempting to improve the properties of avidin, we have
reported earlier [11] that its high pI can be reduced down to
4.7 by site-directed mutagenesis, without a¡ecting the biotin-
binding ability or the stability of the avidin tetramer. In the
present study we mutated the glycosylation site of avidin in
order to produce a non-glycosylated avidin and to explore
whether the complete removal of the oligosaccharide moiety
would generate deleterious e¡ects on the physicochemical and/
or biotin-binding properties of avidin. Moreover we combined
this non-glycosylated avidin with a previously reported charge
mutant of avidin (Avm-pI4.7) to create a mutated non-glyco-
sylated avidin derivative (ngAvm-pI4.7) with additionally im-
proved non-speci¢c binding characteristics. Indeed, it has
been previously shown [9] that enzymatically and chemically
modi¢ed NeutraLite Avidin (deglycosylated and neutral) is
Fig. 5. Non-speci¢c binding of native and mutant avidins to DNA
and cells. The indicated amounts of salmon-sperm DNA or the indi-
cated cell samples (2.5 Wg protein per well) were ¢xed to nitrocellu-
lose strips by slot blotting. Native or mutant avidin samples were
applied, and the amount of avidin per slot was determined using
anti-avidin antibody. Plat, platelets; Hep, hepatocytes; bact, E. coli
cells ; Lym, lymphocytes.
Fig. 4. Sensitivity of the native and mutant avidins to proteolytic di-
gestion by proteinase K. The indicated protein, in the presence or
absence of biotin, was mixed with a 1:50 ratio (w/w) of proteinase
K to target protein, and samples were taken at the designated time
intervals. The samples were dissolved in SDS-containing sample
bu¡er, boiled for 10 min, and subjected to SDS^PAGE. The values
represent the relative percent of intact monomer observed in the in-
dicated sample, graphed as a function of time.
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superior to native avidin in many biotechnological applica-
tions. However, it would be valuable to have a recombinant
form of avidin that lacks the positive charge and oligosaccha-
ride side chain, since the enzymatic and the chemical proce-
dures used for the preparation of NeutraLite Avidin often
lead to a mixture of products, which could a¡ect biotin bind-
ing [29].
As in the case of the charge mutants [11], we again turned
to nature for guidance in designing the non-glycosylated avi-
din, ngAvm. In addition to the avidin gene, the chicken ge-
nome includes at least ¢ve avr’ genes which have recently been
cloned by our group [18]. These avr genes were well conserved
(overall identity over 90%) [19], and when expressed in insect
cells showed strong binding to biotin (K.J. Airenne, unpub-
lished results). Based on comparison of amino acid sequences
of avidin and the avr proteins (Fig. 1), Asn-17 was replaced
with isoleucine instead of the usual alanine, since all the avr
proteins bear Ile in this position. It is interesting to note that
all of the avr’s contain at least one alternative glycosylation
site, i.e. comprising the Asn-Xaa-Ser/Thr sequence (not shown
in the ¢gure). These alternative sites, when modeled into the
known three-dimensional structure of avidin, would be posi-
tioned on the surface of the molecule in close proximity to the
position of Asn-17. Although the potential exists, it is cur-
rently unknown whether or not the avr proteins are indeed
glycosylated in nature.
Based on the interaction analysis by optical biosensor, both
the ngAvm and ngAvm-pI4.7 displayed similar biotin-binding
properties to wild-type avidin. Both these proteins bound to
biotin surface so tightly that practically no dissociation was
detected; the current optical biosensor technology cannot be
used to determine a⁄nities stronger than KaV1012 M. To
further analyze the biotin-binding characteristics of ng-Avm
and ngAvm-pI4.7, 2-iminobiotin surface was used, since avi-
din binds to 2-iminobiotin with lower, measurable a⁄nity and
2-iminobiotin has been previously shown to be a good report-
er for streptavidin-biotin interactions [30]. The kinetic param-
eters and the a⁄nities of binding to 2-iminobiotin were in
both cases similar to wild-type avidin (Table 2) demonstrating
that neither the removal of sugar nor the reduction of pI
caused noticeable e¡ects in biotin-binding ability of avidin.
Removal of the oligosaccharide moiety also had little e¡ect
on the thermal stability characteristics of avidin, since ngAvm
was found to be as stable as the wild-type avidin. The ngAvm-
pI4.7 displayed slightly decreased thermostability properties,
but when bound to biotin it still required temperatures over
80‡C to dissociate (and only partially). Interestingly when
susceptibility to proteinase K was tested, it was observed
that without biotin both ngAvm and ngAvm-pI4.7 were
clearly more sensitive to limited proteolysis than either wild-
type avidin or Avm-pI4.7. However, biotin stabilized all these
proteins and rendered them resistant to proteolysis. It has
been previously shown [24] that in the case of apoavidin,
proteolysis with proteinase K results in limited attack at the
loop between L-strands 3 and 4 (the speci¢c sites of proteol-
ysis are at Thr40-Ser41 and Asn42-Glu43), leaving other parts
of the molecule intact. According to the three-dimensional
structure [20,31], this loop is £exible and accessible to solvent
in apoavidin, but when biotin is bound it becomes ordered
and locks the biotin in the binding site. This behavior of the
3-4 loop is the most likely explanation for resistance of holo-
avidin to proteinase K. Analysis of the three-dimensional
structure of avidin also revealed that the glycosylation site,
Asn-17, is located near the 3-4 loop. It is therefore plausible
that the sugar moiety would protect this loop from proteol-
ysis, since ngAvm and ngAvm-pI4.7 are both degraded at a
substantially faster rate than either wild-type avidin or Avm-
pI4.7.
In a recent article [32], an acidic mutant of chicken avidin
was expressed in E. coli. Despite the presence of a carbohy-
drate-attachment site (Asn16-Met17-Thr18), the gene product
was non-glycosylated as would be expected in a bacterial host
cell system. One of the interesting characteristics of this par-
ticular recombinant acidic avidin was its relatively low re-
sponse to anti-avidin antibodies, to which the authors attrib-
uted an altered antigenicity. An alternative explanation for the
low response to antibodies would be that the acidic mutant
avidin has reduced non-speci¢c binding properties, resulting
in a comparatively low signal when compared to that of the
native (basically charged) chicken avidin. Indeed, all of the
avidin mutants produced in our laboratory proved to be
highly antigenic in properly controlled experiments (Tikva
Kulik, unpublished results).
In summary, we have produced a non-glycosylated avidin
mutant, ngAvm, which bound biotin very tightly and dis-
played thermostability characteristics, similar to those of the
wild-type avidin. These results support the earlier claims [8^
10] that the sugar side-chain is not important for biotin-bind-
ing or for maintaining the high thermostability properties of
native avidin. Secondly, we have combined ngAvm with an
acidic mutant, Avm-pI4.7 [11], to further enhance the proper-
ties of avidin for general application in avidin-biotin technol-
ogy. The resultant non-glycosylated, acidic mutant, ngAvm-
pI4.7, was found to be very stable and to exhibit biotin-bind-
ing activity comparable to that of wild-type avidin. Moreover,
ngAvm-pI4.7 displayed clearly reduced non-speci¢c binding
both to DNA and to di¡erent cell types. This mutant could
therefore be particularly useful in future localization and sep-
aration studies where high background is a problem. Further-
more, the non-glycosylated, acidic avidin may also be applic-
able in a⁄nity-based drug targeting. In this regard, chicken
avidin would be preferable to streptavidin for in vivo studies.
However, one of the problems experienced in using avidin is
its rapid removal from the circulation system. The high pI and
sugar moiety of avidin have been considered as the main
reasons for its rapid clearance [29,33^35], and the mutant
equivalent to NeutraLite Avidin described herein may provide
an elegant solution to this problem.
Finally, although E. coli expression systems are cheaper and
more e⁄cient in most cases when glycosylation is not needed,
production of the avidin mutants in baculovirus-infected in-
sect cells results in a soluble gene product. This is clearly
advantageous over renatured recombinant avidin and strepta-
vidin mutants produced in E. coli. In addition to the baculo-
virus production system used in this study, mutated non-gly-
cosylated avidin genes could also be attractive topics for
production in other eukaryotic systems like yeast, fungi or
plants. Indeed, it has been shown that transgenic corn can
produce high amounts of wild-type avidin [36], and it would
be interesting to apply such a system for the production of
large quantities of non-glycosylated avidin mutants.
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